Abstract:Circulating levels of the pro inflammatory cytokine, interleukin18 (IL18), are elevated in patients with hypertension and chronic kidney disease (CKD). Moreover, genetic deficiency of IL18 prevents the development of one kidney deoxycorticosterone acetate and high salt (DOCA/salt) induced blood pressure (BP) elevation and renal injury. Thus, the current study aimed to determine if pharmacological inhibition of IL18 is similarly protective against elevations in BP, renal inflammation and dysfunction in the DOCA/salt model of hypertension and CKD. Male C57BL/6 mice were randomly assigned to receive either control IgG or anti IL18 neutralising monoclonal antibody (control IgG and mAb; 30 mg/kg, i.p., Novartis, bolus every 3 days). Three days after the first injection, mice were uninephrectomised and treated for a further 21 days with either DOCA (2.4 mg/d, s.c. pellet) with high salt (0.9% in drinking water), or a placebo pellet (s.c.) plus normal drinking water. BP was measured weekly (tail cuff, starting at baseline). Transdermal glomerular filtration rate (tGFR) measurements were recorded at baseline and at endpoint to determine kidney function. Kidneys were harvested at endpoint for histopathological staining, quantitative reverse transcription PCR (RT qPCR) and flow cytometry to assess fibrosis, inflammation and immune cell infiltration, respectively. Baseline systolic BP was not different between mice treated with anti IL18 mAb (118 ± 2 mmHg) versus control IgG (122 ± 3 mmHg). However, anti IL18 mAb treatment significantly blunted hypertensive responses to DOCA/salt, with systolic BP only reaching 139 ± 6 mmHg compared to 159 ± 6 mmHg in control IgG treated animals (Figure; n = 11–12; P < 0.05). Anti IL18 mAb treatment also significantly reduced DOCA/salt induced leukocyte (CD45+) accumulation in the kidneys (0.9 ± 0.1x105 cells/kidney) compared to control IgG treatment (1.6 ± 0.3x105 cells/ kidney; n = 11–12; P < 0.05), which was largely attributed to reduced macrophage accumulation (CD11b+/F4/80+; n = 11–12; P < 0.05). A ∼30% decline in kidney function was observed in DOCA/salt-treated mice that received control IgG, which was associated with renal fibrosis and injury. Impaired kidney function decline (but not fibrosis and injury) appeared to be less severe in DOCA/salt treated mice that received anti IL18 mAb (n = 7). DOCA/salt treatment increased expression of genes associated with renal fibrosis (Col1al, Col3a1 and Col5a1), injury (Kim1 and Ngal) and inflammation (Ifng, Mrc1, II6, Ccl2 etc.). Surprisingly, DOCA/salt induced changes in gene expression were not prevented by anti IL18 mAb treatment. IL18 neutralisation affords protection against DOCA/salt induced hypertension and renal inflammation. Thus. IL18 may represent a potential therapeutic target to treat hypertension and CKD.

BCL6 Attenuates Renal Inflammation Via Negative Regulation of NLRP3 Transcription

BCL6 Attenuates Proliferation and Oxidative Stress of Vascular Smooth Muscle Cells in Hypertension

Abstract 394: Chronic Knockdown of the NTS AT1R Increases Circulating Inflammatory-Endothelial Progenitor Cells Ratio and Exacerbates Hypertension in the SHR

Chronic knockdown of the nucleus of the solitary tract AT1 receptors increases blood inflammatory-endothelial progenitor cell ratio and exacerbates hypertension in the spontaneously hypertensive rat.

Abstract 17594: Brain Microglial Cytokines are Critical for Renin-Angiotensin-Aldoterone-System(RAAS)-Induced Neurogenic Hypertension

Abstract 160: Angiotensin-(1-7) Decreases the Pro-inflammatory Effects of Prorenin in Hypothalamic Microglia

IMPACT OF NLRP3 INFLAMMASOME ON THE DEVELOPMENT OF HYPERTENSION AND RENAL AND CARDIAC HYPERTROPHY IN 2K1C AND DOCA/SALT MICE

Both partial inactivation as well as activation of NF-κB signaling lead to hypertension and chronic kidney disease

Bradykinin 1 receptor blockade subdues systemic autoimmunity, renal inflammation, and blood pressure in murine lupus nephritis

Contribution of TGF-Beta-Mediated NLRP3-HMGB1 Activation to Tubulointerstitial Fibrosis in Rat With Angiotensin II-Induced Chronic Kidney Disease

NLRP3 Gene Deletion Attenuates Angiotensin II-Induced Phenotypic Transformation of Vascular Smooth Muscle Cells and Vascular Remodeling.

IL-18 (Interleukin-18) Produced by Renal Tubular Epithelial Cells Promotes Renal Inflammation and Injury During Deoxycorticosterone/Salt-Induced Hypertension in Mice

Angiotensin Receptor Neprilysin Inhibition mediates Renal Protection by ARNI (Sacubatril Valsartan) in Rats with Spontaneous Hypertension

NTS (pro)renin receptor (PRR)‐mediated antihypertensive effect involves NF‐KappaB‐cytokine signaling in the spontaneously hypertensive rats (SHR)

Abstract P132: Heterogeneously Expressed Bcl6 Controls Endothelial Inflammatory Response

PRR promotes hypertensive renal injury by activating Wnt/β-catenin signaling and inflammation infiltration in mice

Targeting Interleukin-1 Beta to Suppress Sympathoexcitation in Hypothalamic Paraventricular Nucleus in Dahl Salt-Sensitive Hypertensive Rats

PS-B09-13: PHARMACOLOGICAL INHIBITION OF INTERLEUKIN-18 REDUCES DEOXYCORTICOSTERONE/SALT-INDUCED HYPERTENSION AND RENAL INFLAMMATION

Loss of NLRP6 expression increases the severity of acute kidney injury

The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model

Adipokine CTRP6 Improves PPARγ Activation to Alleviate Angiotensin II-induced Hypertension and Vascular Endothelial Dysfunction in Spontaneously Hypertensive Rats.